2023
Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic reviewBreast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 32: 1037-1045. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Original ResearchBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumors
2022
AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers
Lerner G, Tang H, Singh K, Golestani R, St Claire S, Humphrey P, Lannin D, Janostiak R, Harigopal M. AMACR Expression is a Potential Diagnostic Marker in Apocrine Lesions of Breast, and is Associated with High Histologic Grade and Lymph Node Metastases in Some Invasive Apocrine Breast Cancers. Clinical Breast Cancer 2022, 23: 199-210. PMID: 36577560, DOI: 10.1016/j.clbc.2022.11.012.Peer-Reviewed Original ResearchConceptsInvasive ductal carcinomaTriple-negative breast cancerHigh histologic gradeApocrine differentiationAMACR expressionEstrogen receptorApocrine DCISER-/PRHistologic gradeProgesterone receptorApocrine featuresBreast cancerHuman epidermal growth factor 2 (HER2) statusLack of ERDistant metastasis-free survivalDiagnostic markerInitial N stageLack estrogen receptorApocrine breast cancerLymph node metastasisNegative breast cancerAndrogen receptor mRNACoA racemase expressionBenign breast tissueBreast cancer cohort
2018
Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score
Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M. Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score. The Breast Journal 2018, 24: 976-980. PMID: 30230117, DOI: 10.1111/tbj.13117.Peer-Reviewed Original ResearchConceptsLymph node-negative patientsNode-negative patientsOncotype DX testingInvasive carcinomaLow-grade invasive carcinomasHistologic subtypeOncotype DXRecurrence scoreEstrogen receptorHigh riskAJCC Breast Cancer Staging SystemBreast cancer staging systemOncotype DX recurrence scoreFavorable histologic subtypeOncotype recurrence scoreSimple multivariable modelsCancer (AJCC) staging systemRisk of recurrenceDX recurrence scoreOnly significant predictorExcellent prognosisIntermediate riskDuctal carcinomaHistologic gradeHistologic predictorsStrong androgen receptor expression can aid in distinguishing GATA3+ metastases
Boto A, Harigopal M. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases. Human Pathology 2018, 75: 63-70. PMID: 29408697, DOI: 10.1016/j.humpath.2018.01.024.Peer-Reviewed Original ResearchConceptsGATA3-positive tumorsAndrogen receptor expressionBreast originMetastatic settingUrothelial originAR expressionAR stainingAndrogen receptorReceptor expressionBreast cancerUnknown originBreast cancer tissue microarrayMarker of breastStrong AR expressionCancer tissue microarrayMammaglobin expressionUrothelial carcinomaLobular carcinomaProgesterone receptorEstrogen receptorTissue microarrayMammary originCarcinomaGATA3 expressionGATA3
2011
Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal Of Clinical Oncology 2011, 29: 2978-2984. PMID: 21709197, PMCID: PMC3157961, DOI: 10.1200/jco.2010.32.9706.Peer-Reviewed Original ResearchConceptsER-positive patientsEstrogen receptorQuantitative immunofluorescenceBreast cancerTissue microarrayPositive cellsIndependent retrospective cohortsEstrogen receptor measurementsAssessment of survivalTMA cohortFalse-negative resultsRetrospective cohortER immunoreactivityTest discordancePrognostic outcomesIndependent cohortReceptor measurementsLimitations of immunohistochemistryPatientsDiscrepant casesCohortIHC methodPathologists' judgmentsDiscrepant resultsStandardized assays
2010
Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.Peer-Reviewed Original ResearchConceptsDisease-free survivalEstrogen receptorContinuous variablesSouthwest Oncology GroupAQUA methodAC chemotherapyMenopausal statusNegative patientsOncology GroupNode statusSequential doxorubicinPoor outcomeTumor sizeProgesterone receptorPrognostic informationWorse outcomesTissue biomarkersTissue microarrayBiphasic effectP53 expressionPatientsHER2Low expressersDiagnostic approachMultiplexed assessment
2009
Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment.
Rimm D, Barlow W, Harigopal M, Tedeschi G, Peggy P, Yeh I, Haskell C, Livingston R, Hortobagyi G, Hayes D. Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. Cancer Research 2009, 69: 704. DOI: 10.1158/0008-5472.sabcs-704.Peer-Reviewed Original ResearchDisease-free survivalEstrogen receptorHER2 expressionWorse disease-free survivalPoor disease-free survivalContinuous variablesLow HER2 expressionPoor prognostic markerBreast cancer casesBreast cancer therapyBi-phasic effectSame slideHazard ratioMenopausal statusNode statusSequential doxorubicinPoor outcomePrognostic valueTumor sizePrognostic informationWorse outcomesPrognostic markerBreast cancerCancer casesTissue microarray
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discovery